Revenue from operations stood at Rs 961.20 crorefor the quarter under consideration as against Rs 906.31 crore for the same period year ago
Referring to Covid-19, the SBI chairman said that the situation continues to be uncertain and major challenges would arise from extended working capital cycle and waning cash flows
Besides asset quality improvement, management's positive commentary on loan growth and lower that expected moratorium book were key reasons behind the Street's excitement
As crude oil prices tanked globally, owing to a slowdown in industrial activity and demand, BPCL was forced to value finished goods inventory and raw materials at below cost.
It had posted Rs 230 crore PBT during the corresponding quarter last year on a consolidated basis.
While near-term prospects hinge on unlocking of economy, the stock remains a good valuation play, say analysts
Although unsure of revival in demand, Chief Financial Officer Aditya Pande said there was a slight uptick in forward bookings after the lockdown was relaxed.
The FMCG major said that after the initial hiccups, the firm coped up well and witnessed 20 per cent rise in revenues in April, and 28 per cent in May
Full-year pre-tax profit up 4.46% at Rs 331.52 cr
But, analysts have lowered earnings estimate due to high channel inventory
The bank's net interest income (NII) rose by 46 per cent to Rs 2,356 crore in Q4FY20 from Rs 1,609 crore Q4FY19
On a sequential basis, however, the company fared better, both in terms of sales and profits. The stock ended day's trade at Rs 869.8, down 1.3 per cent.
Full-year PBT doubles to Rs 256.26 crore from Rs 127.18 crore
The overall two-wheeler and three-wheeler sales including exports registered 633,000 units in the quarter as against 907,000 units registered in the quarter ended March 2019
The bank's provision coverage ratio improved to 72.48 per cent at end of March 2020, up from 67.16 per cent in March 2019
The total income for the quarter rose 8.84 per cent to Rs 2880.82 crore from Rs 2646.96 crore in the year ago period.
The company had posted a net profit of Rs 635.88 crore in the same period previous fiscal, Sun Pharma said in a BSE filing
Q4 was weak with 8.8% fall in top line and 45.5% decline in pre-tax profit
The company saw its total consolidated revenue in Q4FY20 at Rs 1961 crore, up by a marginal 4.69 per cent over Rs 1873 crore in Q4FY19
After adjusting for fair value adjustments, profit on sale of investment, dividend and provisioning, the adjusted profit before tax for the quarter ended March 31, 2020 is, Rs 3,535 crore